This Article Full Text Full Text (PDF) All Versions of this Article: 51/4/829    most recent HYPERTENSIONAHA.107.104950v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Smith, P. B. Articles by Benjamin, D. K. PubMed PubMed Citation Articles by Smith, P. B. Articles by Benjamin, D. K., Jr Pubmed/NCBI databases Medline Plus Health Information High Blood Pressure Related Collections Health policy and outcome research Clinical Studies

(Hypertension. 2008;51:829.)
© 2008 American Heart Association, Inc.

Original Articles

Safety of Placebo Controls in Pediatric Hypertension Trials

From the Food and Drug Administration (P.B.S., M.D.M., J.L., D.K.B.), Rockville, Md; and the Departments of Pediatrics and Medicine and the Duke Clinical Research Institute (P.B.S., R.M.C., J.L., D.K.B.), Duke University, Durham, NC.

Correspondence to P. Brian Smith, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715. E-mail brian.smith{at}duke.edu

Many clinical trials, including those in pediatric populations, use a placebo arm for medical conditions for which there are readily available therapeutic interventions. Several short-term efficacy trials of antihypertensive medications performed in response to Food and Drug Administration–issued written requests have used a placebo arm; whether the use of a placebo arm is safe in children with hypertension is unknown. We sought to define the rates of adverse events in 10 short-term antihypertensive trials to determine whether these trials resulted in increased risk to pediatric patients receiving placebo. We combined patient-level data from 10 antihypertensive efficacy trials performed in pediatric patients that were submitted to the Food and Drug Administration from 1998 to 2005. We determined the number and type of all of the adverse events reported during the placebo-controlled portion of the clinical trials and compared these numbers between the patients who received placebo and those who received active drug. Among the 1707 children in the 10 studies, we observed no differences in the rates of adverse events reported between the patients who received placebo and those who received active drug. Only 5 patients suffered a serious adverse event during the trials; none were thought by the investigators to be related to study drug, and only 1 occurred in a patient receiving placebo. Short-term exposure to placebo in pediatric trials of antihypertensive medications appears to be safe.

Key Words: pediatric drug therapy • hypertension • placebo-controlled clinical trials • adverse events • medical ethics